Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
ViiV Healthcare announces CHMP positive opinion for Vocabria + Rekambys, the first and only complete long-acting HIV treatment, for adolescents in Europe
Vocabria + Rekambys is the first and only complete long-acting regimen for the treatment of HIV, reducing dosing days from 365 to 6 per year
Download (PDF, 104.2KB) -
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer
Regulatory designation based on promising preliminary clinical data.
Download (PDF, 146.9KB) -
Jemperli (dostarlimab) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer
Designation based on data showing no evidence of disease in 100% of all 42 patients who completed treatment with dostarlimab.
Download (PDF, 183.9KB) -
Jemperli (dostarlimab) plus chemotherapy receives positive CHMP opinion to expand approval to all adult patients with primary advanced or recurrent endometrial cancer
Positive opinion based on statistically significant and clinically meaningful progression-free and overall survival data.
Download (PDF, 195.8KB) -
Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
DREAMM-7 trial shows sustained overall survival benefit for Blenrep (belantamab mafodotin) combination versus daratumumab combination
Download (PDF, 231.4KB) -
US FDA accepts GSK’s submission for the use of Nucala (mepolizumab) in COPD
Nucala could be the first approved biologic with monthly dosing for patients with COPD
Download (PDF, 188.3KB) -
Blenrep (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma
Regulatory submission supported by phase III head-to-head DREAMM-7 trial showing statistically significant efficacy.
Download (PDF, 140.2KB) -
GSK and Zhifei revise and extend strategic vaccine collaboration in China
Shingrix collaboration extended to 2034
Download (PDF, 233.8KB) -
First single-dose medicine for P. vivax malaria prequalified by WHO and included in WHO Guidelines
Important steps to advance access to first single-dose malaria treatment
Download (PDF, 164.0KB) -
GSK’s fully liquid Menveo meningococcal vaccine approved by European Commission
Formulation supports simplification of vaccination process against invasive meningococcal disease (IMD).
Download (PDF, 172.3KB) -
Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy.
Download (PDF, 147.9KB) -
Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan
First RSV vaccine approved in Japan to help protect 50-59 year olds at increased risk due to certain underlying health conditions.
Download (PDF, 141.3KB) -
Statement: GSK continues to show strong leadership in its Access to Medicines Index ranking
GSK is pleased to rank 2nd in the Access to Medicine Index (ATMI) in its ninth wave.
Download (PDF, 123.5KB) -
Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC)
Primary endpoint met with a statistically significant improvement in itch over 24 weeks compared with placebo
Download (PDF, 174.0KB) -
Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma
Full data to be presented at 2024 American Society of Hematology Annual Meeting in December.
Download (PDF, 139.7KB) -
GSK highlights key data from hepatology portfolio at the AASLD’s The Liver Meeting® 2024, emphasising patient impact in areas of high unmet need
New data shows potential for sequential therapy of bepirovirsen after daplusiran/tomligisiran to further increase functional cure rates.
Download (PDF, 279.3KB) -
New GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers
GSK’s Your Cancer Is Our Challenge will raise awareness of barriers and inspire future solutions to address them, beyond treatment.
Download (PDF, 163.3KB) -
GSK on track to deliver 2024 outlooks with further good progress made in R&D
Q3 2024 performance highlights
-
GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
Agreement reinforces GSK’s portfolio in the treatment of lupus and underlying drivers of autoimmune disease
Download (PDF, 134.6KB) -
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD.
Download (PDF, 244.1KB)
